Meadow Creek Investment Management’s 10x Genomics TXG Stock Holding History

Meadow Creek Investment Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$249K	Buy	+4,944	New	+$274K	﹤0.01%	960

Other funds holding TXG

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

JCM

JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Meadow Creek Investment Management's TXG Position: Q3 2019 in Review

Meadow Creek Investment Management opened a new position in 10x Genomics (TXG) in Q3 2019: 4,944 shares worth $249K. The stake represents ﹤0.01% of the portfolio and ranks #960 among its holdings.

92 funds tracked by Wall St. Rank hold TXG as of Q3 2019.

Meadow Creek Investment Management held 4,944 shares of 10x Genomics worth $249K as of Q3 2019.
10x Genomics was a new Meadow Creek Investment Management position in Q3 2019.
10x Genomics made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #960 holding.
92 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.